BIOCYTOGEN PHARMA. H YC1 (I54) - Total Liabilities

Latest as of December 2025: €1.54 Billion EUR ≈ $1.81 Billion USD

Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) has total liabilities worth €1.54 Billion EUR (≈ $1.81 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of BIOCYTOGEN PHARMA. H YC1 to track the company's year-over-year net asset growth rate.

BIOCYTOGEN PHARMA. H YC1 - Total Liabilities Trend (2021–2025)

This chart illustrates how BIOCYTOGEN PHARMA. H YC1's total liabilities have evolved over time, based on quarterly financial data.

BIOCYTOGEN PHARMA. H YC1 Competitors by Total Liabilities

The table below lists competitors of BIOCYTOGEN PHARMA. H YC1 ranked by their total liabilities.

Company	Country	Total Liabilities
Jiangsu Province Commun SHG:603018	China	CN¥6.96 Billion
Criteo S.A F:CI5A	Germany	€902.62 Million
Jinzai Food Group Co Ltd SHE:003000	China	CN¥863.30 Million
Beijing Fengshangshiji Culture Medi SHE:300860	China	CN¥232.78 Million
Mega First Corporation Bhd KLSE:3069	Malaysia	RM1.55 Billion
Supriya Lifescience Limited NSE:SUPRIYA	India	Rs1.21 Billion
Shenmao Technology Inc TW:3305	Taiwan	NT$6.84 Billion
Ningxia Xinri Hengli Steel Wire Rope Co Ltd SHG:600165	China	CN¥2.27 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down BIOCYTOGEN PHARMA. H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOCYTOGEN PHARMA. H YC1 market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.31	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.71	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.41	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BIOCYTOGEN PHARMA. H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BIOCYTOGEN PHARMA. H YC1 (2021–2025)

The table below shows the annual total liabilities of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€1.54 Billion ≈ $1.81 Billion	-2.02%
2024-12-31	€1.58 Billion ≈ $1.84 Billion	-4.96%
2023-12-31	€1.66 Billion ≈ $1.94 Billion	+0.60%
2022-12-31	€1.65 Billion ≈ $1.93 Billion	+56.93%
2021-12-31	€1.05 Billion ≈ $1.23 Billion	--

About BIOCYTOGEN PHARMA. H YC1

F:I54 Germany Biotechnology

Market Cap

$702.88 Million

€601.21 Million EUR

Market Cap Rank

#10834 Global

#1244 in Germany

Share Price

€5.60

Change (1 day)

+6.67%

52-Week Range

€1.81 - €6.90

All Time High

€6.90